•
MG
MGTX
MeiraGTx Holdings plc Ordinary Shares
yahooBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
614.15M
Volume
504.69K
52W High
$9.73
52W Low
$4.55
Open
$0.00
Prev Close
$7.32
Day Range
0.00 - 0.00
About MeiraGTx Holdings plc Ordinary Shares
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Latest News
Eli Lilly Expands Genetic Eye-Disease Focused Pipeline With MeiraGTx Gene Therapy Collaboration
Benzinga•Nov 10
MeiraGTx Sales Jump 1,133 Percent
The Motley Fool•Aug 14
AAV for the Hereditary Retinal Diseases Clinical Trial Pipeline Analysis Demonstrates 70+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
GlobeNewswire Inc.•Aug 5
Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases
GlobeNewswire Inc.•May 21
Parkinson’s Disease Therapeutic Domain Projected to See Transformational Growth Across the 7MM During the Study Period (2020–2034) | DelveInsight
GlobeNewswire Inc.•Apr 22
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies
GlobeNewswire Inc.•Mar 4
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research•May 8
MeiraGTx to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.•Apr 24